home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2993.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
38 lines
Document 2993
DOCN M94A2993
TI Chemotherapy and didanosine (DDI) in AIDS-lymphoma.
DT 9412
AU Harrington WJ; Ucar A; Cabral L; Lai S; Byrnes JJ; Univ. of Miami, FL.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):178 (abstract no. PB0138). Unique
Identifier : AIDSLINE ICA10/94369582
AB OBJECTIVE: To explore the hypothesis that combined antiretroviral and
antitumor chemotherapy is feasible and more effective. METHOD: A
randomized clinical trial was undertaken of stage II-IV intermediate or
high grade lymphoma. 16 pts were randomized to the DDI (+) arm and 14 to
the DDI (-) arm. Chemotherapy was delivered over 12 weeks: mitoxantrone
(8 mg/m2) and VP-16 (100 mg/m2) on odd weeks; cyclophosphamide 350 mg/m2
on wks 1, 5, and 9; bleomycin (10 u/m2) and vincristine 2 mg on even
weeks; and methylprednisolone (1g/m2) weekly. In addition, patients
received prophylaxis with Bactrim, difluconazole and acyclovir. RESULTS:
The response rate in the DDI(+) arm was 85% (61% CR and 25% PR) versus
71% (43% CR and 28% PR) in the DDI (-) arm. The median duration of CR
has been 50+ weeks. Logistic regression analyses show that a higher CD4
count, a higher CD8 count, a higher serum albumin, a lower serum lactic
dehydrogenase, and DDI usage were associated with complete remission and
longer survival. DDI toxicities included: pancreatitis, paresthesias,
and diarrhea. There was less febrile neutropenia in the DDI (+) arm.
CONCLUSIONS: Concurrent chemotherapy and DDI is feasible and well
tolerated. This treatment program is delivered over a short period of
time (12) weeks, with acceptable toxicity and a high response rate.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY/ PATHOLOGY
Antineoplastic Agents, Combined/*THERAPEUTIC USE Combined Modality
Therapy Comparative Study Didanosine/*THERAPEUTIC USE Dose-Response
Relationship, Drug Drug Administration Schedule Follow-Up Studies
Human Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY/PATHOLOGY
Neoplasm Staging Remission Induction Survival Rate CLINICAL TRIAL
MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).